

A SAS macro to fit Flexible Parametric Survival Models: Applications of the Royston- Parmar models

explanation and examples

June, 2014

Ron Dewar
Cancer Care Nova Scotia, Halifax, Canada
Ifty Khan
UCL Cancer Trials Centre, London, UK



Flexible parametric survival models

credit where it is due:

Royston and Parmar (2002 *Stats in Medicine*)

- and others

Lambert, P (2009 *Stata Journal*) for Stata program `stpm2`
and its extensions



Flexible parametric survival models

Why parametric survival models?

- Inclusion of more prognostic factors (or continuous factors) argues against stratification
- Communication of results
- Special applications (eg. economic models)
- Some quantities that might be of interest
 - hazard rate function
 - absolute differences between groups
 - crude probability of death
 - 'postponable' deaths
 - cure models
 - mean survival



Flexible parametric survival models

Some advantages:

- Use of restricted cubic splines for hazard function
- Models in continuous time (no time splitting)
- Model at individual level
- Survival and hazard functions can be derived and manipulated
- Intuitive specification of non-proportional effects
- Quantify absolute effects
- Prediction at any time point, for any set of covariates



Sas macro suite for ✓ Royston-Pamar models

- modeled on Stata programs *stpm2*, *predict* and *rcsgen*
- tested in sas 9.2 – 9.4
- Uses *nlmixed* for estimation, *iml* for post-estimation predictions
- Fits on cumulative log hazard scale
- Allows for cohort and period definitions of risk time
- Relative survival regression, competing risks
- Model fits and prediction equations are generated automatically from user specifications
- Point and interval estimates



Analysis of a Clinical Trial*

comparing sas and stata results

	Cox	Weibull	R-P(3)
	Hazard Ratio (SE)		
Sas	0.95 (0.08)	0.93 (0.09)	0.94 (0.08)
Stata	0.95 (0.08)	0.93 (0.09)	0.94 (0.07)
	Predicted 6 month survival treatment arm vs placebo		
Sas	40.1 vs 38.4	39.6 vs 37.3	
Stata	40.1 vs 38.4	39.6 vs 37.3	

* 'Topical' trial: erlotinib vs placebo (Lee, et al 2012)

Application to Cancer Surveillance

Colorectal cancer patients (n = 3,800 1,200 deaths)
diagnosed in NS 2007 – 2011, follow-up to end of 2011
DCOs excluded (zero length survival causes problems)

Covariates:

- age (in years) at diagnosis

- sex

- stage (summary I – IV)

Effect of stage on hazard is time-dependent

Display hazard plots, hazard differences,
hazard ratios



Examples of macro calls

Model fit:

```
%sas_stpm2( sex stage2 stage3 stage4 age1 age2 age3 ,  
            scale=hazard, df=3,  
            tvc = stage2 stage3 stage4,      dftvc = 2 ) ☺
```

Hazard plot (for specified age and sex):

```
%predict( haz, hazard, at = sex:1 ) ☺
```

Hazard difference (stage II vs stage I)

```
%predict( hdiff, haz_diff, hdiff1 = sex:1 stage2:1 zero  
                                hdiff2 = sex:1           zero ) ☺
```

Hazard ratio (stage II vs stage I):

```
%predict(hr, hratio,  
           hrnum = sex:1 stage2:1 zero  
           hrdenom = sex:1 zero ) ☺
```



Effect of age on hazard

What have we learned by estimating a non-linear effect of age on survival?

Since age is NOT a time-varying component of the model, display hazard ratio with a fixed age as the reference

Example: Males CRC, Female breast cancer (similar model with age, stage) 😊



Example 2

modeling relative survival (proceed with caution)

Net mortality (probability of death):

chances of death by year n , as if cancer were the only possible cause of death

= $(1 - \text{Relative survival})$

Crude mortality:

chances of death by year n , when patient may die of non-cancer cause first

implies a competing risks framework

can be estimated from a relative survival model



Crude probability of death

Some computational details:

underlying model for hazard:

general (all causes) mortality + excess (cancer) mortality

general mortality : population life tables

excess mortality : relative survival model

requires numerical integration of product of survival and hazard functions




Colorectal Survival

probability of death by 5 years
men, by age at diagnosis

			Crude (%)	
	stage	Net (%)	cancer	other causes
age 55	I	6	6	3
	II	10	10	3
	III	24	24	3
	IV	88	87	1
age 85	I	21	18	40
	II	33	27	38
	III	66	52	30
	IV	100	95	4

Crude Probability of Death

Men, Colorectal Cancer



Conclusions

Flexible parametric survival modeling allows for new ways to explore the impact of patient characteristics on survival

hazard plot

hazard difference

hazard ratio

time-dependent covariate effects

non-linear effects of covariates

Sas macros facilitate fitting and display

Work in progress:

'cure' models

'avoidable' deaths

mean survival




Parameter estimates (partial) log hazard ratio, SE


Parameter	Estimate	SE	t-value	Prob t
sex	-0.1704	0.05904	-2.89	0.0039
stage2	-1.1815	0.5186	-2.28	0.0228
stage3	-0.8290	0.5672	-1.46	0.1439
stage4	2.3917	0.4759	5.03	<.0001
age1	1.2696	0.7418	1.71	0.0871
age2	-0.4028	0.1241	-3.25	0.0012
age3	-0.03837	0.03716	-1.03	0.3019
rsc1	0.7911	0.05978	13.23	<.0001
rsc2	2.3442	0.4854	4.83	<.0001
rsc3	-0.1399	0.02335	-5.99	<.0001
...				




Colorectal cancer hazard plots (women, age 65)



Colorectal cancer hazard difference plots, women, age 65 by stage, vs stage I



Colorectal cancer hazard ratio plots, women, age 65 by stage, compared to stage I



Hazard Ratio plot by age, adjusted for stage
Colorectal cancer in men, Female breast cancer

